Postoperative Complications in Colorectal Surgery: Unveiling the Potential of Serum Calprotectin as a Biomarker
Postoperative infections are a leading cause of morbidity and mortality following colorectal surgery, with anastomotic leakage (AL) being a particularly detrimental complication. Early detection of AL is crucial for improving patient outcomes, yet current biomarkers like white blood cell count (WBC), C-reactive protein (CRP), lactate, and procalcitonin (PCT) have limitations in sensitivity and specificity. But here's where it gets intriguing: serum calprotectin (CIS), a protein stored in neutrophils, is emerging as a promising biomarker for postoperative complications, particularly due to its intestinal specificity.
A Pilot Study Unfolds
A recent pilot study published in BMC Surgery (2025) investigated the potential of CIS as a biomarker for postoperative complications in colorectal surgery. The study aimed to define the normal postoperative course of CIS and compare it with established biomarkers like WBC, CRP, lactate, and PCT. Researchers also explored CIS levels in patients with benign versus malignant diseases and those with and without complications.
Key Findings and Controversies
The study revealed several noteworthy findings:
- Postoperative CIS Increase: CIS levels significantly increased postoperatively compared to preoperative values, similar to WBC and CRP.
- Malignant Disease and CIS: Patients with malignant disease exhibited significantly higher preoperative CIS levels than those with benign disease, potentially due to tumor-induced inflammation.
- Complications and CIS: Patients with postoperative complications had significantly higher CIS levels on the first and fifth postoperative days compared to those without complications.
- Correlation with CRP: CIS correlated strongly with CRP on the third postoperative day in patients with complications.
The Debate: CIS vs. Established Biomarkers
While the study highlights CIS's potential, it also sparks debate. The authors acknowledge that CIS did not outperform established biomarkers like CRP or WBC in terms of sensitivity and specificity. However, they argue that CIS's intestinal specificity and rapid release from neutrophils make it a valuable addition to the biomarker arsenal. And this is the part most people miss: the study suggests combining CIS with other inflammatory markers for improved early complication detection, a strategy that warrants further investigation.
Limitations and Future Directions
The study's small sample size and heterogeneous surgical procedures limit generalizability. Additionally, the single case of AL observed restricts conclusions about CIS's predictive power for this specific complication. Future research should focus on larger cohorts, standardized surgical procedures, and exploring CIS kinetics in special populations, such as emergency surgery patients.
Thought-Provoking Questions
- Can CIS be a game-changer in early detection of postoperative complications, or will it remain a supplementary biomarker?
- How can we optimize the use of CIS in combination with other biomarkers for improved patient outcomes?
- What are the cost-effectiveness and accessibility implications of incorporating CIS testing into routine postoperative care?
As the debate surrounding CIS continues, one thing is clear: this pilot study has opened new avenues for research, inviting further exploration and discussion in the pursuit of better patient care.
